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Lee Ann Baxter-Lowe,1 Martin Maiers,2 Stephen R. Spellman,2 Michael D. Haagenson,3
Tao Wang,4 Marcelo Fernandez-Vina,5 Steven G. E. Marsh,6 Mary Horowitz,4
Carolyn Katovich Hurley7HLA disparity between hematopoietic stem cell donors and recipients is one of the most important factors
influencing transplant outcomes, but there are no well-accepted guidelines to aid in selecting the optimal
donor among several HLA mismatched donors. In this report, HLA-A is used as a model to illustrate factors
that are barriers to delineating the relationship between specific HLA mismatches and transplant outcomes
in the United States. Patients in this investigation received transplants for hematologic malignancies that were
facilitated by the National Marrow Donor Program (NMDP) between 1990 and 2002 (n5 4226). High-res-
olution HLA typing was performed for HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, -DPA1, and -DPB1. HLA-A
mismatches were observed in 745 donor-recipient pairs and 62% of these pairs also had disparities at HLA-B,
-C, and/or -DRB1. The HLA-A mismatches involved 190 different combinations of HLA-A alleles and 51% of
these were observed in only 1 pair. Addition of a single HLA-A disparity when HLA-B, -C, and -DRB1 were
matched (n5 282) was associated with increasedmortality (odds ratio [OR]5 1.32, confidence interval [CI]
1.07-1.63). When HLA-B, -C, and -DRB1 were matched, the most frequent HLA-A mismatches were HLA-
A*0201:0205 (n5 28), HLA-A *0301:0302 (n5 15), HLA-A *0201:0206 (n5 15), HLA-A *0201:6801 (n5
12), HLA-A*0101:1101 (n5 11), and HLA-A*0101:0201 (n5 10). There were no statistically significant re-
lationships between any of these disparities and transplant outcomes (engraftment, acute and chronic graft-
versus-host disease [aGVHD, cGVHD] relapse, treatment-related mortality [TRM], or overall survival [OS])
when adjustments for multiple comparisons were considered. Achieving 80% power to detect an effect of
any 1 of these 6 HLA-A disparities on survival is estimated to require a total transplant population of
11,000 to more than 1 million U.S. donor-recipient pairs depending upon the HLA disparity. Thus, alternative
approaches are required to develop a clinically relevant ranking system for specific HLA disparities in the
United States.
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For bonemarrow transplantation (BMT), one of the
few factors that the physician can modify to improve
transplant outcomes is donor compatibility [1]. An
HLA identical donor is optimal, but matched donors
are not available for most patients. It is often necessary
to prioritize several candidate donorswho have different
HLA disparities. For example, it may be necessary to
choose between (1) a mismatch at the HLA-A or
HLA-DRB1 locus, (2) an allele-level mismatch and an
antigen-level mismatch, or (3) an allele with 1 amino
acid difference and another with 3 amino acid differ-
ences. There is limited and sometimes contradictory
evidence to support these decisions. Many factors in-
cluding numerous confounding clinical variables, limi-
tations in the ability to adjust for the effects of multiple971
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the size of data sets are barriers to solving this problem
[2,3].
For studies comparing different HLA loci, HLA-
A, -B, -C, and -DRB1 disparities have most consis-
tently been associated with adverse outcomes [1,4-8].
In 1 of the largest of these studies, there was a 9% to
10% decrement in survival for each HLA-A, -B, -C,
or -DRB1 mismatch [1]. Several studies have sug-
gested differences between allele-level and antigen-
level disparities [4,8], but 1 of the largest studies using
a rigorous statistical model did not confirm this rela-
tionship for a single allele versus a single antigen level
mismatch [1]. It has been more difficult to detect
associations between HLA-DQ and -DP disparities
and transplant outcomes, but associations have been
reported under certain conditions [1,6,9-11].
Some recent clinical investigations have attempted
to investigate particular HLA mismatches or specific
amino acid differences. A Japanese study reported 15
combinations ofmismatched alleles and6 specific amino
acid differences that were associated with graft-versus-
host disease (GVHD) [12]. Because large numbers of
comparisons were required to detect this small number
of statistically significant combinations and there were
many confounding variables, independent confirmation
or other supporting data are essential [13]. An interna-
tional study focused on disparities involving HLA-A*02
alleles reported that mismatches between HLA-A*0201
and HLA-A*0206 were deleterious, but mismatches
betweenHLA-A*0201 andHLA-A*0205 were tolerated
[14]. Interestingly, HLA-A*0201 and HLA-A*0206 are
distinguished by a single amino acid difference at
position 9. HLA-A*0201 and HLA-A*0205 have the
same amino acid difference along with 2 additional mis-
matched amino acids. The HLA-A*0206 mismatches
were predominantly observed in Japanese patients,
whereas the HLA-A*0205 mismatches were in non-
Japanese patients.
Fundamental knowledge about the molecular
mechanisms underlying allorecognition should be use-
ful in prioritizing HLA mismatches. There is a large
body of research using animal models as well as in vitro
assays that show that the molecular characteristics of
MajorHistocompatibility Complex (MHC) disparities
influence allorecognition. Alloreactive T lymphocytes
play a key role in graft rejection, GVHD, and graft-
versus leukemia (GVL) effects. These T cells respond
to differences between HLA molecules and/or peptide
antigens bound by HLA molecules [15,16]. Elsner
et al. [17] used these concepts to rank HLA disparities
based upon the number of amino acid differences
between HLA molecules with adjustments for amino
acid position and a similarity index (Risler score).
However, in vitro and clinical observations have not
supported this particular approach [18,19]. Another
algorithm, HLA Matchmaker, which uses amino acidtriplets within theHLAmolecule, showed some prom-
ise in solid organ transplantation, but was not useful
for BMT [20].
The long-term goal of this investigation is to uti-
lize a combination of fundamental knowledge about
allorecognition along with clinical outcomes to de-
velop a new system for evaluating candidate donors
who are HLA mismatched. The purpose of the study
described here is to delineate the HLA factors that
need to be considered to investigate the impact of
HLA disparities and to test the hypothesis that there
are certain common HLA disparities that are deleteri-
ous. HLA-A was selected as the model for testing this
hypothesis because HLA-A mismatches have been
associated with adverse outcomes in every large clini-
cal investigation, and a recent NMDP report suggests
that mismatches at HLA-A or -DRB1 may have
greater effects on survival than HLA-B or -C mis-
matches [1]. The data reported here show the limita-
tions posed by the diversity of HLA disparities in
unrelated donor transplants performed in the United
States and present transplant outcomes for the most
frequent HLA-A disparities.MATERIALS AND METHODS
Patients
This investigation was approved by the National
Marrow donor Program (NMDP) institutional review
board. Adults transplanted under the auspices of the
NMDP between 1990 and 2002 for acute myelogenous
leukemia (AML), acute lymphoblastic leukemia (ALL),
chronicmyelogenous leukemia (CML),myelodysplastic
syndrome (MDS), or non-Hodgkin lymphoma (NHL)
who had high resolution typing for HLA-A, -B, -C,
-DRB1, -DQA1, -DQB1, -DPA1, and -DPB1 were eli-
gible for this investigation. The subject population was
adjusted as described previously to correct for potential
bias thatmay have been created by consent practices [1].
Early-stage diseasewas defined asAMLandALL infirst
complete remission (CR), CML in first chronic phase,
and MDS subtype refractory anemia (RA). Intermedi-
ate-stage disease was AML or ALL in second or subse-
quent CR or in first relapse, and CML in accelerated
phase or second chronic phase. Advanced-phase disease
was AML in second or higher relapse or primary
induction failure, CML in blast phase, MDS subtypes
refractory anemia with excess blasts (RAEB) or in trans-
formation, orMDS,nototherwise classified.NHLcases
were not classified for disease stage.
Characteristicsof thepatients (n5 4226) anddonors
are provided in Supplemental Table 1. Demographic
data were submitted by the transplant centers and sub-
jected to a rigorous quality assurance process including
on-site auditing againstmedical records, doubledata en-
try, on-line edit checks, and review of the data for
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The majority of the recipients and donors were
Caucasian (recipients: 87% and donors: 85%). For cases
where race was reported for both donor and recipient,
87% of the pairs reported the same race/ethnicity. The
majority of patients receivedmyeloablative (MA) condi-
tioning regimens (93%) and calcineurin inhibitor-based
GVHD prophylaxis (78%).
HLA Matching
Allele-level HLA typing was performed for HLA-
A, -B, -C,-DRB1, -DQ, and -DP using methods that
were previously described in detail [21]. Briefly,
DNA-based HLA typing was based on exons 2 and 3
for HLA Class I and exon 2 for HLA Class II. Known
null alleles were excluded using serologic typing or ex-
tended DNA-based typing.
HLA mismatching was determined by comparing
the peptide sequences encoded by the exons that were
used for HLA typing (ie, exons 2 and 3 for HLA Class
I and exon 2 for HLA Class II) using a sequence data-
base for the human major histocompatibility complex
(MHC) [22]. Low-resolution HLA mismatches were
defined as differences in the first 2 digits of the HLA
types (eg, HLA-A*0101 versus HLA-A*0201), and
high-resolution mismatches were defined as differ-
ences in only the last 2 of 4 digit HLA types (eg,
HLA-A*0201 versus HLA-A*0205). Particular combi-
nations of mismatched alleles in this study are reported
as HLA locus*first allele:second allele. For example,
a mismatch involving HLA-A*0101 and HLA-
A*0201 is denoted A*0101:0201. HLA-DQ and -DP
disparities were not included in the assessment of over-
all HLAmatching because mismatches at these loci did
not individually have detectable effects on survival. If
a donor had a homozygousHLA type and the recipient
was heterozygous at the same locus, the mismatch was
treated as a unidirectional mismatch for GVHD. Con-
versely, mismatches were treated as unidirectional for
engraftment if a recipient had a homozygous HLA
type and the donor was heterozygous.
For analysis of HLA-A mismatches, the orienta-
tion of amino acid side chains was based upon the
position of the side chain in HLA-A crystal structures
[23-25] as well as peptide contact residues defined by
Chelvanayagam [26]. Molecular graphics images
were produced using the UCSF Chimera package
from the Resource for Biocomputing, Visualization,
and Informatics at the University of California, San
Francisco.
Clinical Outcomes
The primary endpoint for this analysis was overall
survival (OS), which was defined as the time from graft
infusion (day 0) to death from any cause. Several
secondary endpoints were also examined. Engraftmentwas defined as maintaining an absolute neutrophil
count (ANC).500 106/L for 3 consecutivemeasure-
ments by day 28. Acute GVHD (aGVHD) was graded
using the Glucksberg scale [27], and chronic GvHD
(cGVHD) was graded using the method of Shulman
et al. [28].Disease relapse was defined using criteria de-
termined by the Center for International Blood and
Marrow Transplant Research (CIBMTR). Treat-
ment-related mortality (TRM) was defined as death
while in continuous CR from the primary disease.Statistics
Continuous variables are presented as the medians
and ranges. Categorical variables are reported as per-
centages. The Kaplan-Meier estimator was used for
determining probabilities for survival endpoints with
variance estimated by Greenwood’s formula. Compar-
isons of survival curves were done with the log-rank
test. Multivariate analyses were performed using the
proportional hazards model to compare the HLA
matched and mismatched groups. Models were fit to
determine which risk factors may be related to a given
outcome. All models were tested for significant clinical
covariates including disease, disease stage, Karnofsky
performance status, donor-patient cytomegalovirus
(CMV) serology, patient race, patient age, T cell de-
pletion, use of total body irradiation (TBI), graft
source (peripheral blood (PB) or BM), donor age, pa-
tient-donor sex match, and year of transplant. Models
included any clinical factors that were related to a given
outcome at P\ .05. All variables were tested for the
affirmation of the proportional hazards assumption.
Factors violating the proportional hazards assumption
were adjusted first before the stepwise model building
approach was used in developing models for the pri-
mary and secondary outcomes. Because of multiple
comparisons, a threshold of P\ .01 for the main effect
was used for significance.RESULTS
Characteristics of HLA-A Disparities
HLA-Amismatcheswere observed in 745donor-re-
cipient pairs, and 62% of these pairs also had disparities
at HLA-B, -C, and/or -DRB1. One of the factors that
many transplant centers use to classify HLA disparities
is the level of typing resolution required to detect the
mismatch: high-resolution types (allele-level) or low-
resolution types (antigen level). Figure 1 shows that
these classifications are generally indicative of the num-
ber of amino acid differences between 2 HLA-A mole-
cules with low-resolution mismatches having 3-28
amino acid differences and high-resolution mismatches
having 1-6 amino acid differences. For low-resolution
disparities, there are a mean 13.5 amino acid differences
Figure 1. Number of mismatched amino acid residues in each HLA-A disparity in 4226 donor-recipient pairs.
Table 1. Amino Acids that Are Different in the Largest
Number of HLA-A Mismatch Combinations
Amino Acid
Position*
HLA-A Mismatch
Combinations (n)
9 105
62 99
63 72
70 74
76 84
77 76
97 91
114 97
116 71
156 90
152 85
*Based upon numbering of amino acids in the mature protein.
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aminoaciddifferences. In this study there are4 ‘‘low-res-
olution’’mismatch combinations that have only 3 amino
aciddifferences:A*0101:3601 (n5 2),A*2301:2402 (n5
11), A*2601:6601 (n5 8), andA*3101:3303 (n5 3).The
HLA-A mismatches with the largest number of amino
acid differences (n 5 28) are A*2301:3601 (n 5 1) and
A*2301:6601 (n5 1).
High-resolutionHLA-Amismatches have only 1-6
mismatched amino acids (mean 2,median 2). Six amino
acid differences are observed in only 1 relatively un-
common disparity, A*3001:3004 (n5 2). In this dataset
there are 26 different HLA-A high resolution mis-
matches that have a single amino acid difference. These
single amino acid differences are located at 19 different
positions within the HLA-A molecule (3, 9, 19, 36, 54,
66, 70, 74, 87, 97, 99, 102, 116, 127, 131, 144, 156, 163,
and 171). Ten of these are predicted to have side chains
that contact the peptide bound to the HLA molecule
[26]. These data show that HLA disparities defined
by a single amino acid difference constitute a diverse
group, because the functional role of the mismatched
amino acid is extremely variable.
There has been interest in determining ifHLAmis-
matches involving particular amino acid positions are
associated with unfavorable outcomes. In general, the
amino acid positions that are observed in the largest
number of different mismatch combinations (Table 1)
influence the peptide binding groove of the HLAmol-
ecule (Figure 2). However, there are also 54 different
amino acid positions that are involved in only 1 mis-
match combination. These are distributed throughout
the HLA molecule and each of these combinations is
infrequent (1-5 observations/combination). Because
the impact of a particular amino acid position is influ-
enced by the molecular context of the amino acid dis-
parity, position alone is unlikely to be sufficient for
predicting effects. Position 9 exemplifies the potentialfor numerous interactions that are likely to confound
comparisons that are focused on particular positions
within the HLA molecule. In this study, position 9 is
mismatched in 389 of the HLA-A disparities and these
disparities involve 105 different combinations ofHLA-
Amolecules.Threeof these combinations involve a sin-
gle amino acidmismatch (n5 64) with themajority be-
ing A*0201:0206 (n 5 60). The remaining mismatch
combinations that involve a difference in position 9
have up to 27 additional amino acid differences. The
most frequent numbers of additional amino acid differ-
ences are 4 (n5 67, 3 combinations), 12 (n5 47, 7 com-
binations), and11 (n5 41,9 combinations).Considering
this extensive variability, a study grouping any amino
acid difference at position 9 is questionable from the
functional perspective.
Many of the highly variable amino acid posi-
tions are predicted to influence the peptides that
can bind to the HLA molecule and/or their precise
position within the peptide binding groove. This
can be examined using 9 peptide environments
that have been shown to alter the amino acid
Figure 2. Structure of HLA*6801. Amino acids that are observed in
the largest number of different mismatch combinations are distributed
throughout the peptide binding domain. The side chains of the amino
acids that are observed in the largest numberof different mismatch com-
binations are shown on an HLA-A*6801 structure (2HLA in the Protein
Data Bank). Molecular graphics images were produced using the UCSF
Chimera package from the Resource for Biocomputing, Visualization,
and Informatics at the University of California, San Francisco.
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peptide [26]. In the donor-recipient pairs in this study,
more than half of the 54 amino acid positions that were
disparate influence these peptide binding environ-
ments. If the frequency of each mismatch combination
is considered, the amino acids that are most often mis-
matched are all located in positions that alter these
9 peptide binding environments: positions 9 (n 5
389), 76 (n 5 255), 97 (n 5 251),114 (n 5 251), 156
(n 5 362), 152 (n 5 248), 77 (n 5 241), 95 (n 5 239),
62 (n 5 229), 70 (n 5 225), and 116 (n 5 204), where
n is the number of donor-recipient pairs with a mis-
match at the position. With the exception of position
95, these frequently mismatched amino acids influence
several of the 9 peptide binding environments. The ef-
fects on peptide binding are expected to be extremely
variable.Multiple HLA Disparities
The clinical impact of a particularHLA-Adisparity
may be confounded by the effects of additional mis-
matches at otherHLA loci.The high frequency ofmul-
tiple HLA locus mismatches is demonstrated in
Figure 3, which shows each amino acid position that
was mismatched at HLA-A in this subject population
along with the proportion of mismatches that involve
additional mismatches at HLA-B, -C, and -DRB1.
Overall, 62% of the HLA-A mismatches are
accompanied by additional disparities at HLA-B, -C,
and/or -DRB1.Most Frequent HLA-A Disparities
Table 2 lists the 16 HLA-A disparities that were
observed at least 10 times in the entire data set (includ-
ing those with additional mismatches at HLA-B, -C,
and/or DRB1). Investigating the effects of particular
HLA mismatches or mismatched positions is simpli-
fied by focusing on single HLA mismatches, because
strategies to compensate for additional disparities are
currently suboptimal. If HLA-A disparities are consid-
ered only when HLA-B, -C, and -DRB1 are matched,
there are only 6 mismatch combinations that are ob-
served at least 10 times in a population of 4226 trans-
plants. These HLA-A mismatch combinations have
very different properties including differences in the
number of mismatched amino acids (1-24 amino acids,
Table 4). One common feature is that all of them have
at least 1 amino acid difference located in a position
that is predicted to influence the peptides bound to
the HLA molecules.Clinical Outcomes for the Most Frequent HLA-
A Disparities
Because knowledge regarding the interactions
caused by multiple HLA disparities is extremely lim-
ited, outcomes analysis was limited to pairs having
a single HLA-A mismatch with matching at HLA-B,
-C, and -DRB1. To select the reference population,
donor-recipient pairs with 8/8 matches (HLA-A, -B,
-C, and -DRB1), 12/12 matches (HLA-A, -B, -C,
-DRB1, -DQA1, and -DQB1), and 16/16 matches
(HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, -DPA1,
and -DPB1) were compared. For OS, there were no
differences between the 16/16 matched group and
those with HLA-DP mismatches (12/12 matches,
odds ratio [OR] 5 1.00, 95% confidence interval
[CI] 0.84-1.18) or those with HLA-DP and/or -DQ
mismatches (8/8 matches, OR 5 1.01, 95% CI 0.80-
1.29). Therefore, the 8/8 matched group was used as
the reference group for pairs withHLA-Amismatches.
A single disparity at the HLA-A locus was associated
with increased mortality (OR 5 1.32, 95% CI 1.07-
1.63).
To determine if it is possible to detect detrimental
effects of any of the most common HLA-A mismatches,
transplant outcomes were examined for HLA-A mis-
matches that were observed in at least 10 pairs when
HLA-B, -C, and -DRB1 were matched. There are only
6 HLA-A mismatches that met these criteria:
A*0201:0205, A*0301:0302, A*0201:0206, A*0201:6801,
A*0101:1101, and A*0101:0201 (Table 3). The patient
and donor characteristics of these pairs that are provided
in Table 3 show that there were no major differences
among these groups. For OS, with relatively small num-
bers of patients there are no statistically significant differ-
ences betweenpairswith theseHLAdisparities and the 8/
8 matched pairs (data not shown). The most common
Figure 3. Amino acid differences that are involved in HLA-A disparities are distributed throughout the peptide binding domain, present in both low-
resolution (LR) and high-resolution (HR) mismatches, and often accompanied by mismatches (MM) at HLA-B, -C, and -DRB1 loci. The position and side-
chain orientation of each mismatched amino acid are indicated below the x-axis (A5 alpha helix, B5 beta sheet, and C5 connecting loop). The amino
acids that aremost frequently mismatched line the peptide binding groove of theHLAmolecule. Most of themismatched amino acids are involved in both
low- and high-resolution mismatches.
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95%CI 0.86-4.80, P5 .07), but this did not reach statis-
tical significance. Multivariate results for survival of pairs
with the 6 HLA mismatches compared with the 8/8
matched pairs has an overall P-value of .075.
For severe aGVHD (grades III-IV), the overall P-
value for comparison of these mismatches with 8/8
matches is .014, and data for the individual HLA-A
mismatches are shown in Table 4. Interestingly,Table 2. HLA-A Disparities Observed in at Least 10 Donor-
Recipient Pairs
HLA MM
Number of
Observations in
4226 Pairs
Number of
Observations in
HLA-B, -C, -DRB1
Matched Pairs (%)
Number of
Mismatched Amino
Acids
0201-0205 65 28 (43) 4
0201-0206 60 15 (25) 1
6801-6802 34 7 (21) 5
0201-6801 30 12 (40) 12
0301-0302 27 15 (56) 2
3001-3002 23 7 (30) 4
0101-1101 23 11 (48) 11
0301-1101 19 8 (42) 7
0101-0301 19 9 (47) 15
2901-2902 17 6 (35) 1
2402-2403 17 9 (53) 2
0201-0202 16 4 (25) 3
0101-0201 13 10 (77) 24
2501-2601 12 7 (58) 7
3101-3201 12 5 (42) 12
2301-2402 11 3 (27) 3
MM indicates mismatched.A*0201:0206, which was found to have an association
with aGVHD in another study [12], is approaching
significance in this study (OR 5 3.22, 95% CI 1.02-
10.50, P 5 .03). There were no significant differences
detected for engraftment (overall P-value .36),
cGVHD (overall P-value 5 .28), relapse (overall P-
value 5 .19), TRM (overall P-value 5 .14), or dis-
ease-free survival (DFS) (overall P-value 5 .18) (data
not shown).DISCUSSION
One of the major challenges in BMT is selection of
themost compatible donor when anHLAmatched do-
nor is not available. Although several investigations
have attempted to determine which HLA disparities
are poorly tolerated, the results have often been con-
tradictory. The investigation reported here uses one
of the largest study populations to date (n 5 4226) to
illustrate that extensive HLA diversity is a major bar-
rier to establishing the association between HLA dis-
parity and transplant outcomes.
HLA-A was selected for this investigation because
mismatches at this locus have beenmost consistently as-
sociatedwith adverse transplant outcomes [1,4,5,12]. In
the 4226pairs examined in this investigation, therewere
190 differentHLA-Amismatch combinations and 51%
of these were observed in only 1 pair. Very fewHLA-A
disparities were observed frequently enough to study.
Table 3. Demographics of Patients andDonors for the 6Most FrequentHLA-ADisparities in HLA-B, -C, and -DRB1Matched Pairs
A*0201-A*0205 A*0301-A*0302 A*0201-A*0206 A*0201-A*6801 A*0101-A*1101 A*0101-A*0201
Variable N (%) N (%) N (%) N (%) N (%) N (%)
Patients (n) 28 15 15 12 11 10
Centers (n) 22 12 13 9 7 8
Patient Age
Median (years) 27 37 23 32 42 29
Range (years) 1-51 9-58 3-51 1-54 2-50 13-45
<20 years 7 (25) 1 (6) 7 (46) 4 (34) 2 (18) 4 (40)
20-39 years 14 (50) 7 (47) 4 (27) 4 (33) 3 (27) 5 (50)
40+ years 7 (25) 7 (47) 4 (27) 4 (33) 6 (55) 1 (10)
Male sex 14 (50) 7 (47) 10 (67) 7 (58) 4 (36) 7 (70)
Karnofsky$ 90 21 (78) 12 (80) 12 (80) 8 (73) 7 (64) 9 (90)
Disease
AML 7 (25) 1 (7) 5 (33) 5 (42) 3 (27) 4 (40)
ALL 10 (36) 1 (7) 3 (20) 1 (8) 0 0
CML 6 (21) 11 (73) 7 (47) 3 (25) 6 (55) 4 (40)
MDS 4 (14) 2 (13) 0 2 (17) 2 (18) 2 (20)
NHL 1 (4) 0 0 1 (8) 0 0
Disease status
Early 7 (25) 9 (60) 6 (40) 4 (33) 4 (36) 6 (60)
Intermediate 11 (39) 4 (27) 9 (60) 5 (42) 4 (36) 2 (20)
Advanced 8 (29) 2 (13) 0 1 (8) 1 (9) 1 (10)
Other 2 (7) 0 0 2 (17) 2 (18) 1 (10)
Marrow 28 (100) 15 (100) 15 (100) 11 (92) 10 (91) 9 (90)
Conditioning
Ablative 27 (96) 14 (93) 15 (100) 12 (100) 11 (100) 10 (100)
Other 1 (4) 1 (7) 0 0 0 0
GVHD Prophylaxis
FK506 5 (18) 2 (13) 2 (13) 4 (33) 0 1 (10)
CsA 17 (61) 10 (67) 13 (87) 6 (51) 10 (91) 6 (60)
T cell depletion 6 (21) 3 (20) 0 1 ( 8) 1 (9) 3 (30)
Other 0 0 0 1 ( 8) 0 0
Donor/recipient sex match
M/M 10 (36) 6 (40) 7 (47) 4 (33) 2 (18) 3 (30)
M/F 10 (36) 3 (20) 3 (20) 2 (17) 5 (46) 2 (20)
F/M 4 (14) 1 ( 7) 3 (20) 3 (25) 2 (18) 4 (40)
F/F 4 (14) 5 (33) 2 (13) 3 (25) 2 (18) 1 (10)
Donor/recipient CMV match
N/N 14 (50) 7 (47) 2 (14) 3 (25) 5 (46) 4 (40)
N/P 6 (22) 6 (40) 3 (20) 2 (17) 3 (27) 2 (20)
P/N 4 (14) 0 5 (33) 1 ( 8) 2 (18) 3 (30)
P/P 4 (14) 2 (13) 5 (33) 5 (42) 1 ( 9) 0
Unknown 0 0 0 1 ( 8) 0 1 (10)
Donor age (years) Median (range) 40 (20-57) 39 (21-50) 36 (20-53) 36 (29-47) 39 (22-53) 38 (22-49)
Year of transplant
1990-1994 6 (21) 3 (20) 3 (20) 1 (8) 3 (27) 5 (50)
1995-2002 22 (79) 12 (80) 12 (80) 11 (92) 8 (73) 5 (50)
Follow-up median months (range) 60 (48-101) 111 (36-144) 61 (22-99) 77 (35-97) 90 (60-157) 55 (34-154)
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome;
NHL, non-Hodgkin lymphoma; GVHD, graft-versus-host disease; CsA, cyclosporine; N, number; M, male; F, female; CMV, cytomegalovirus.
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donor-recipient pairs (A*0201:0205, A*0201:0206,
A*6801:6802, A*0201:6801). Sixteen and HLA dispar-
ities were observed in 10 or more donor-recipient pairs
(Table 2). If pairs with additional HLA-B, -C, and
-DRB1 disparity are excluded to diminish confounding
HLA variables, only 6 mismatch combinations occur in
10 or more pairs (Table 4). Because the most frequent
HLA-A mismatches in HLA-B, -C, and -DRB1
matched pairs occur only 2-6 times/1000 U.S. patients,
it is not feasible to directly determine associations be-
tween a particular HLA-A disparity and transplant
outcomes for patients transplanted in the United
States.One of the goals of this investigation was to iden-
tify frequent HLA disparities that are deleterious.
However, there were only 6 mismatch combinations
observed more than 10 times in HLA-B, -C, and
-DRB1 matched pairs and when survival of each of
these small groups was compared with that of the
HLA-matched control group, no statistically signifi-
cant associations were detected. A*0201:0205, the
most frequent HLA-A disparity observed when
HLA-B, -C, and -DRB1 were matched, had a trend to-
ward increased mortality at 1 year (P 5 .07, OR 5
2.08, 95% CI 0.86-4.80). A study from the 14th Inter-
national Histocompatibility Workshop examined 51
pairs with A*0201:0205 mismatches using additional
Table 4. Transplant Outcomes for the 6 Most Frequent HLA-A Disparities in HLA-B, -C, and -DRB1 Matched Pairs
HLA Mismatch A*0201:0205 A*0301:0302 A*0201:0206 A*0201:6801 A*0101:1101 A*0101:0201
Number of amino acid differences 4 2 1 12 11 24
Position and single-letter code for amino acid differences 9FY 43QR 152EV 9FY 9FY 9FY 44KR
95VL 156LQ 62GR 44KR 62QG
156LW 63EN 67MV 66NK
66KN 70HQ 67MV
70HQ 76AV 74DH
74HD 77ND 76AV
95VI 150VA 77ND
97RM 156RQ 90DA
107WG 158VA 95IV
114HR 166DE 97IR
116YD 167GW 107GW
156LW 114RH
116 DY
127NK
142IT
145RH
150VA
152AV
156RL
158VA
163RT
105PS
166DE
167GW
N 27* 15 15 11* 11 9*
OR for survival 2.08 1.10 2.64 2.52 1.13 0.86
95% CI 0.86-4.80 (P 5 .07) 0.25-3.73 0.81-8.38 0.60-9.94 0.19-4.74 0.09-4.55
OR for acute GVHD 1.41 1.03 3.22 1.06 2.35 0.0
95% CI 0.55-3.33 0.24-3.48 1.02-10.50 (P 5 .03) 0.18-4.43 0.56-9.29 0.0-1.12
OR indicates odds ratio; CI, confidence interval; GVHD, graft-versus-host disease.
*Three cases (A*0201:0205, A*0201:6801, and A*0101:0201) were not included in the multivariate analysis because of missing data.
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tect any association between this disparity and survival
[14]. Additional donor recipient pairs are required to
evaluate the impact of this disparity.
A trend for increased severe aGVHD was detected
for one of the most frequent mismatches, A*0201:0206
(OR5 3.22, 95% CI 1.02-10.50, P5 .03). This is pro-
vocative because 2 recent publications reported associa-
tions between A*0201:0206 and adverse outcomes.
Kawase et al. [12], who studied transplants facilitated
by the JapanMarrowDonorProgram (JMDP), reported
that a graft fromanA*0206donor to anA*0201 recipient
was significantly associated with GVHD (OR 5 1.78,
P\.001).Ananalysis of data fromthe14thInternational
Histocompatibility Workshop suggested that A*0201:
0206 mismatches were associated with mortality. One
limitation in these 2 studies is that it is likely that there
is some overlap in the subjects because many of the
A*0201:0206 mismatched pairs examined in the Work-
shop were obtained from the JMDP. Nevertheless, the
A*0201:0206mismatchcombinationhasnowbeen iden-
tified as a potential risk factor in several studies, suggest-
ing that this particular mismatchmay be associated with
a GVHD and perhaps mortality.
A high incidence of certain HLA-A disparities in
the JMDP data set allowed Kawase et al. [12] to exam-
ine directional differences in HLA disparities. For ex-
ample, in their analysis an A*0201 donor:A*0206recipient was not detrimental (OR 5 1.23, P 5 .22),
whereas A*0201 recipient:A*0206 donor (OR 5 1.78,
P \ .001) was significantly associated with GVHD.
In their study, there were 3 HLA-A disparities that
were associated with aGVHD, and all of these associ-
ations were directional. The possibility of directional
effects has also been suggested by laboratory studies
involving B*4402:4403 where (1) in vitro assays, (2)
characteristics of the peptides bound by the 2 HLA
molecules, and (3) crystal structures of the molecules
have shown that the same peptide in the HLA binding
groove can have different orientations in HLA-B*4402
and *4403. These differences can be recognized by T
lymphocytes [15,16,29,30], and may be clinically im-
portant [31,32]. For studies involving heterogeneous
patient populations such as those from the NMDP,
there are too few subjects with particular HLA dispar-
ities to further subdivide the mismatches according to
their presence in the donor or recipient and this limi-
tation may obscure significant effects.
One of the striking differences between reports
from the JMDP and NMDP data sets is the incidence
of particular HLA disparities. A study of 5210 subjects
whose transplants were facilitated by the JMDP
reported very large frequencies for certain HLA-A
mismatch combinations: A*0201:0206 (n 5 269),
A*2402:2420 (n 5 90), and A*2601:2603 (n 5 69).
The allelic lineages HLA-A2, A26, and A24 present
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trast, the European populations present only a limited
number of alleles in these groups because there is a pre-
dominant allele in each lineage. TheNMDP data set is
largely composed of patients and donors with Euro-
pean ancestry where most of the pairs are HLA
matched for common alleles and the mismatches often
involve low-frequency alleles.
Using the frequencies of the 6 most commonHLA-
A disparities observed in this study when HLA-B, -C,
and -DRB1 are matched and the 100 day mortality dif-
ference observed between each disparity and an 8/8
match, the number of U.S. donor recipient pairs needed
to achieve 80% power to detect an association with sur-
vival ranges from 11,000 to more than 1.3 million, de-
pending upon the HLA mismatch (Table 5). For
example, it is estimated that 72 pairs with a single
A*0201:0205 would be required to achieve 80% power
to detect an association with survival versus an 8/8
match. Using the frequency of 27 pairs with this HLA
disparity in 4226 subjects, it is estimated that 11,269
pairs would be required to detect an association with
survival. Attempts to overcome this limitation by in-
cluding pairs with multiple HLA mismatches creates
another problem—adjusting for the effects of particular
HLA disparities which are not yet well understood.
One alternative that has been explored is to inves-
tigate the impact of mismatching particular amino
acids within the HLA molecule. Kawase et al. [12]
used bootstrap analysis to examine each amino acid in-
volved in an HLA mismatch and concluded that 2 spe-
cific amino acid substitutions in HLA-A were
associated with aGVHD: position 9 Tyr versus Phe
and position 116 Asn versus Asp [12]. This approach,
however, has some limitations, and the conclusions
about some specific residues may be biased because
context of the amino acid differences is ignored. For
example, in the NMDP data set residue 9 can be mis-
matched along with 0-28 additional amino acids;
a large body of laboratory investigation suggests that
context of an amino acid difference is crucial forTable 5. Number of Subjects Needed to Achieve 80% Power
for Detecting an Association with 100 day Mortality for the 6
Most Frequent HLA-A Disparities in HLA-B, -C, and -DRB1
Matched Pairs*
HLA-A
Mismatch
Number of
Mismatches in
4,226 Subjects
Number
Required for
80% Power
Total Number
of Subjects
Required to
Achieve 80%
Power
A*0201:0205 27 72 11,269
A*0301:0302 15 4687 1,320,484
A*0201:0206 15 39 10,988
A*0201:6801 11 43 16,520
A*0101:1101 11 2653 1,019,234
A*0101:0201 9 2014 945,685
A*2402:2403 8 30 15,848
*Using the difference observed between each group and an 8/8 match.allo-recognition. The analysis conducted by Kawase
et al. [12] may also be confounded by the occurrence
of additional HLA mismatches in each donor-recipi-
ent pair. In this scenario specific amino acid mis-
matches may occur in 1 or a few mismatch
combinations that may be accompanied by an addi-
tional mismatch in another locus as the result of link-
age disequilibrium. Therefore, the effect attributed
to a particular amino acid mismatch at a given locus
may, in fact, result from the occurrence of multiple
mismatches. Another concern is that multiple compar-
isons were made in the study by Kawase et al. [12].
Multiple comparisons without support from func-
tional data can detect relationships that are statistically
significant, but may not be clinically or biologically
relevant [13]. In vitro assays may help to clarify the sit-
uation for certain HLA disparities [34], but this ap-
proach is not practical for studying the large number
of combinations of HLAmismatches that are observed
in clinical transplantation.
This study shows that extraordinary diversity of
HLA creates complexity related to multiple HLA dis-
parities between donor and recipient along with differ-
ences in the context in which each amino acid
difference occurs within HLA molecules. Decades of
research in transplant immunology have taught us
that these are important factors influencing the ability
to stimulate a clinically significant response against an
alloantigen. Unfortunately, the relatively large study
population examined here (n 5 4226) provides only
a few examples for investigation, and none of these
have sufficient subjects to apply robustmultivariate sta-
tistical approaches. Given extensive HLA polymor-
phism and complex biology, it is unlikely that the
approaches described above will be successful in rank-
ing the relative risks ofmost of theHLAdisparities that
are encountered in clinical practice in the United
States. Although it may be possible to study certain
HLA disparities in specific populations such as the Jap-
anese, these observationsmay not extend to other racial
and ethnic groups because there may be other genetic
differences that influence immune responses.
There have been attempts to identify permissive and
detrimental HLA disparities using characteristics of
HLA mismatches. Several studies have classified HLA
disparities based upon typing resolution: low-resolution
(antigen level) and high-resolution (allele level) mis-
matches. This approach assumes that HLAmismatches
detected by serologic HLA typing reagents (ie, low res-
olution) have different clinical effects that those that are
not.The reported studies have been conflictingwith the
largest detecting no statistically significant difference
for a single allele versus a single antigen mismatch [1].
One explanation is that this comparison does not ade-
quately classify HLA mismatches according to their
risk.Thenumber and functionof amino aciddifferences
in each of these groups is diverse, and those with 3-6
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lution HLA disparities (Figure 1).
Scoring systems that group HLA disparities based
upon their similarity have also been explored. One ap-
proach that assigned scores to HLA disparities based
upon the number, position, and properties of the amino
acid differences has not correlated well with clinical
outcomes [18,19]. This may, in part, be caused by ob-
servations showing that the number of mismatched
amino acids may not correlate with T lymphocyte re-
sponses [34].Duquesnoy et al [20] have created an algo-
rithm that has shown some promise in solid organ
transplantation, but ranking by this approach has not
correlated with outcomes in a NMDP data set.
Although these attempts have not been successful,
approaches that combine HLA disparities using simi-
lar functional characteristics have the highest likeli-
hood for success in studying populations that have
a large number of low frequency HLA disparities.
One possibility would be to establish a group in which
the amino acid differences are predicted to only alter
the peptide binding groove (PBG group) versus all
others, or perhaps subsets thereof defined by differ-
ences in epitopes for T, B, and NK lymphocytes. In
this scenario, many high-resolution mismatches that
have only 1 amino acid difference in the peptide bind-
ing groove (eg, A*0201:0206) would be classified in the
PBG group. Classification of HLA mismatches that
have amino acid differences outside the peptide bind-
ing groove is more complicated. There is evidence
suggesting that there are 6 amino acids that are
frequently involved in docking of T cell receptors
[35]. If these positions are the same between 2 HLA
molecules and there are differences in the peptides
bound by the HLA molecule, positive selection of T
lymphocytes on a similar HLA surface may increase
the frequency of alloreactive T lypmphocytes. In this
case, A:0201:0206, which several studies suggest may
be associated with adverse transplant outcomes, may
be detrimental because T cells selected by similar
docking residues respond to subtle differences in pep-
tides bound by the HLA molecule. HLA disparities
with differences in T cell contact residues may be
less problematic [34]. Others such as A*0202:0224
would be classified in another group because some of
the amino acid differences are located in loops that
are predicted to create epitopes for alloantibodies.
ExtremeHLAdiversity, genetic variation involving
other factors influencing immune responses, and nu-
merous factors influencing transplant outcomes (eg,
disease and stage of disease, recipient age) create a for-
midable challenge for achieving compelling data to de-
velop well accepted guidelines for ranking the HLA
mismatches in potential donors. Until this problem
can be solved, it is tempting to use available reports
with statistically significant comparisons to guide do-
nor selection. The observations reported here illustratesome of the limitations of published investigations and
the need for caution in using the available data to guide
donor selection. Ultimately, sophisticated models will
likely be required to address this important question.ACKNOWLEDGMENTS
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